Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP-1203-R
- Development stage
- Unknown
- Lead developer
- NVP Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NVP-1203-R** is an NVP Healthcare clinical comparator regimen associated with the aceclofenac and eperisone program for acute low back pain. Available trial records indicate that it was administered orally and consists of separately administered NVP-1203-R1 and NVP-1203-R2 components; in the related NVP-1203 program, the active substances are aceclofenac and eperisone hydrochloride. Aceclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and reduces prostaglandin synthesis, while eperisone is a centrally acting skeletal-muscle relaxant with sodium- and calcium-channel inhibitory effects. NVP-1203-R was evaluated as an active comparator in a completed Phase 3 acute low back pain study. ([ichgcp.net](https://ichgcp.net/zh/clinical-trials-registry/NCT04082975))
- Other names
- Aceclofenac and Eperisone fixed-dose combination
02
Targets
ADRA1A (α1A)CaV (Voltage-gated calcium channel protein complex)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on NVP-1203-R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVP-1203-R.